Document ID: chunk:federal_register_of_legislation:F2025C00183:clause:1_73316
Version: federal_register_of_legislation:F2025C00183
Segment Type: clause
Provision Reference: sch 1 cl 73316
Character Range: 284206–284781

73316              Measurable residual disease (MRD) testing by a quantitative patient‑specific molecular assay performed on bone marrow (or, in a patient with T‑cell acute lymphoblastic leukaemia, performed on a peripheral blood sample if bone marrow cannot be collected) from a patient diagnosed with acute lymphoblastic leukaemia treated with combination chemotherapy or after salvage therapy, requested by a specialist or consultant physician practising as a haematologist or oncologist, other than a service associated with a service to which item 73313 applies  780.00